関: measles-mumps-rubella vaccine

WordNet

immunogen consisting of a suspension of weakened or dead pathogenic cells injected in order to stimulate the production of antibodies (同)vaccinum
the basic unit of money in Belarus

PrepTutorEJDIC

牛痘種,痘苗(牛痘を起こすビールスで,天然痘予防のために人体に接種される) / (伝染病の病原菌から作った)ワクチン
=German measles

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/10/22 15:22:30」(JST)

wiki en

[Wiki en表示]

Rubella vaccine is a vaccine used against rubella.^[1] One form is called "Meruvax".^[2]

Rubella vaccine is included in combination vaccines such as:

MMR vaccine, containing vaccine for rubella as well as measles vaccine and mumps vaccine
MMRV vaccine, containing vaccine for rubella as well as measles, mumps and varicella vaccine

A vaccine was first licensed in 1969.^[3] It is on the World Health Organization's List of Essential Medicines, the most important medication needed in a basic health system.^[4]

Medical uses

The rubella vaccine should be administered to non-pregnant females who have tested nonimmune or have a rubella titer less than 1:10. It is contraindicated during pregnancy and if low titre is found during pregnancy, it should be administered only after delivery in order to protect the future pregnancies. It is also advisable to avoid becoming pregnant for the 4 weeks following the administration of the vaccine.^[5] As rubella causes upper respiratory disease that leads to complications of pneumonia and bronchitis, rubella vaccine is beneficial to control exacerbations of chronic obstructive pulmonary disease (COPD) and asthma.

Society and culture

It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.^[4]

References

^ Josefson D (March 2001). "Rubella vaccine may be safe in early pregnancy". BMJ 322 (7288): 695. doi:10.1136/bmj.322.7288.695/b. PMC 1119900. PMID 11264203.
^ Weibel RE, Caserta V, Benor DE, Evans G (March 1998). "Acute encephalopathy followed by permanent brain injury or death associated with further attenuated measles vaccines: a review of claims submitted to the National Vaccine Injury Compensation Program". Pediatrics 101 (3 Pt 1): 383–7. doi:10.1542/peds.101.3.383. PMID 9481001.
^ Atkinson, William (2011). Epidemiology and Prevention of Vaccine-Preventable Diseases (12 ed.). Public Health Foundation. pp. 301–323. ISBN 9780983263135. Retrieved Mar 2015.
^ ^a ^b "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.
^ Marin, M; Güris, D; Chaves, SS; Schmid, S; Seward, JF; Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention, (CDC) (22 June 2007). "Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP).". MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control 56 (RR-4): 1–40. PMID 17585291.

External links

Rubella Immunisation on patient.co.uk
Rubella virus vaccine on MedicineNet
Rubella on vaccines.gov

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 風疹 rubella
2. 妊娠中の予防接種 immunizations during pregnancy
3. リスクの高い成人に対する麻疹-ムンプス-風疹ワクチン接種 measles mumps rubella vaccination in high risk adults
4. 妊娠中の風疹 rubella in pregnancy
5. 関節炎の原因となる特定のウイルス specific viruses that cause arthritis

English Journal

Susceptibility to cytomegalovirus, parvovirus B19 and age-dependent differences in levels of rubella antibodies among pregnant women.

Barlinn R1, Vainio K, Samdal HH, Nordbø SA, Nøkleby H, Dudman SG.Author information 1Department of Virology, Norwegian Institute of Public Health, Oslo, Norway.AbstractInfections caused by cytomegalovirus (CMV), parvovirus B19 (B19), and rubella can lead to serious complications in pregnant women. The aim of this study was to determine the susceptibility to CMV, B19, and rubella antibodies in pregnant women in Norway. Consecutive sera samples were collected from pregnant women in two different regions in Norway. Sera were collected from age groups; ≤19, 20-24, 25-29, 30-34, 35-39, and ≥40 years old. Of the 2,000 pregnant women tested, anti-CMV IgG was positive in 62.8% anti-parvovirus B19 IgG in 59.7% and anti-rubella IgG in 94.4%. CMV IgG susceptibility has decreased in pregnant women less than 30 years of age, from 60% in a study conducted in 1973-1974 to 37.2% in present study. There was a significant difference in CMV IgG seropositivity rate between the two regions (58.6% and 67.1%). Serum levels of rubella IgG was lowest in age group 25-29 years with a positivity rate of 91.0%. Women born before vaccination with two doses of MMR started, had both a higher positivity rate and significantly higher levels of rubella antibody titre, 96.1% and 82.2 IU/ml compared to those born after 92.9% and 41.7 IU/ml. Significantly lower anti-rubella IgG titre found in the youngest age groups highlights the need for continued antenatal screening. A considerable increase in anti-CMV-IgG seropositivity rate was observed and might be associated with higher rate of breastfeeding and a higher percentage attending day-care centres. J. Med. Virol. 86:820-826, 2014. © 2013 Wiley Periodicals, Inc.
Journal of medical virology.J Med Virol.2014 May;86(5):820-6. doi: 10.1002/jmv.23757. Epub 2013 Sep 30.
Infections caused by cytomegalovirus (CMV), parvovirus B19 (B19), and rubella can lead to serious complications in pregnant women. The aim of this study was to determine the susceptibility to CMV, B19, and rubella antibodies in pregnant women in Norway. Consecutive sera samples were collected from p
PMID 24114849

Development of a multivalent paediatric human vaccine for rabies virus in combination with Measles-Mumps-Rubella (MMR).

Fooks AR1, Koraka P2, de Swart RL2, Rupprecht CE3, Osterhaus AD2.
Vaccine.Vaccine.2014 Apr 11;32(18):2020-1. doi: 10.1016/j.vaccine.2014.02.065. Epub 2014 Feb 28.
PMID 24589425

Associations between race, sex and immune response variations to rubella vaccination in two independent cohorts.

Haralambieva IH1, Salk HM2, Lambert ND1, Ovsyannikova IG1, Kennedy RB1, Warner ND3, Pankratz VS3, Poland GA4.Author information 1Mayo Vaccine Research Group, Mayo Vaccine Research Group, Mayo Clinic, Guggenheim 611C, 200 First Street SW, Rochester, MN 55905, United States; Program in Translational Immunovirology and Biodefense, Mayo Clinic, Rochester, MN 55905, United States.2Mayo Vaccine Research Group, Mayo Vaccine Research Group, Mayo Clinic, Guggenheim 611C, 200 First Street SW, Rochester, MN 55905, United States.3Division of Biostatistics, Mayo Clinic, Rochester, MN 55905, United States.4Mayo Vaccine Research Group, Mayo Vaccine Research Group, Mayo Clinic, Guggenheim 611C, 200 First Street SW, Rochester, MN 55905, United States; Program in Translational Immunovirology and Biodefense, Mayo Clinic, Rochester, MN 55905, United States; Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN 55905, United States. Electronic address: poland.gregory@mayo.edu.AbstractINTRODUCTION: Immune response variations after vaccination are influenced by host genetic factors and demographic variables, such as race, ethnicity and sex. The latter have not been systematically studied in regard to live rubella vaccine, but are of interest for developing next generation vaccines for diverse populations, for predicting immune responses after vaccination, and for better understanding the variables that impact immune response.
Vaccine.Vaccine.2014 Apr 7;32(17):1946-53. doi: 10.1016/j.vaccine.2014.01.090. Epub 2014 Feb 13.
INTRODUCTION: Immune response variations after vaccination are influenced by host genetic factors and demographic variables, such as race, ethnicity and sex. The latter have not been systematically studied in regard to live rubella vaccine, but are of interest for developing next generation vaccines
PMID 24530932

Japanese Journal

風疹含有ワクチンの接種対象年齢の変遷と妊婦の風疹抗体保有率 : 1施設における観察研究

國吉保孝,加村梓,安田すみ江 [他]
日本プライマリ・ケア連合学会誌 = an official journal of the Japan Primary Care Association 37(2), 99-103, 2014-06
NAID 40020112040

Seroprevalence of rubella in the cord blood of pregnant women and congenital rubella incidence in Nha Trang, Vietnam

Miyakawa Masami,Yoshino Hiroshi,Yoshida Lay Myint,Vynnycky Emilia,Motomura Hideki,Tho Le Huu,Thiem Vu Dinh,Ariyoshi Koya,Anh Dang Duc,Moriuchi Hiroyuki
Vaccine
… To investigate susceptibility to and factors associated with rubella infection among pregnant mothers and to estimate the burden of congenital rubella infection (CRI) in Vietnam where rubella-containing vaccine (RCV) is not included in the routine immunization program, we conducted a prospective cohort study in Nha Trang, Vietnam between 2009 and 2010. …
NAID 120005438859

風疹HI抗体価別によるワクチン接種ブースターの長期効果

寺田喜平,赤池洋人,荻田聡子 [他]
感染症学雑誌 = The journal of Japanese the Association for Infectious Diseases 88(1), 110-116, 2014-01
NAID 40019974382

Related Pictures

Never mind the science: Anti-vaccine tide difficult to stem Measles, mumps and rubella vaccine not linked to autism, study says New measures to secure MMR vaccine for private patients - GOV.UK MMR vaccine is effective and does not cause autism, study confirms Pediatrician breaks down how measles, mumps and rubella vaccine works [Video] MMR vaccine does not cause autism, another study confirms : science Chew On This, Anti-Vaxxers: America Has Wiped Out Rubella MMR vaccine: Safety, efficacy, and who should have it

★リンクテーブル★

拡張検索	「measles-mumps-rubella vaccine」

「measles-mumps-rubella vaccine」

Rubella vaccine
Vaccine description
Target disease	Rubella
Type	Attenuated virus
Clinical data
MedlinePlus	a601176
Identifiers
CAS Registry Number
ATC code	J07BJ01
(what is this?) (verify)

　　[★] 麻疹・ムンプス・風疹ワクチン

[pmid11264203-1] Josefson D (March 2001). "Rubella vaccine may be safe in early pregnancy". BMJ 322 (7288): 695. doi:10.1136/bmj.322.7288.695/b. PMC 1119900. PMID 11264203.

[pmid9481001-2] Weibel RE, Caserta V, Benor DE, Evans G (March 1998). "Acute encephalopathy followed by permanent brain injury or death associated with further attenuated measles vaccines: a review of claims submitted to the National Vaccine Injury Compensation Program". Pediatrics 101 (3 Pt 1): 383–7. doi:10.1542/peds.101.3.383. PMID 9481001.

[CDC2012Pink-3] Atkinson, William (2011). Epidemiology and Prevention of Vaccine-Preventable Diseases (12 ed.). Public Health Foundation. pp. 301–323. ISBN 9780983263135. Retrieved Mar 2015.

[World_Health_Organization-4] "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.

[5] Marin, M; Güris, D; Chaves, SS; Schmid, S; Seward, JF; Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention, (CDC) (22 June 2007). "Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP).". MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control 56 (RR-4): 1–40. PMID 17585291.

匿名

検索

案内

案内

rubella vaccine